CD160 was identified on 0.86 ± 0.2%, 0.59 ± 0.2% and 0.82 ± 0.5% of OAC cells in treatment-naïve, post-FLOT and post-CROSS OAC tumour biopsy tissue, respectively (Fig. 6). This evidence concerns the gene CD160 and neoplasm.